Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer

NCT01827943 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT01827943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01827943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer
Lead sponsor
Institut Bergonié
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
December 31, 2016
Enrollment
54 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed bladder cancer